

PTO/SB/64 (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE uction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PETITION FOR REVIVAL OF AN APPLICATION FOR PATENT

Docket Number (Optional) CIP OF 09/828.589

ABANDONED UNINTENTIONALLY UNDER 37 CFR 1.137(b)		CIP OF 09/828,589	
First named inventor: ROLF BUNGER			
Application No.: 10/643,080	Art Unit: 1616		
Filed: AUGUST 19, 2003	Examiner: NIKKI HANDY		
Title: CELLULAR PHOSPHORYLATION POTENTIAL ENHANCING COMPOSIT	IONS, PREPARATIO	ON AND USE THEREOF	ŀ
Attention: Office of Petitions Mail Stop Petition Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450			
FAX (571) 273-8300 NOTE: If information or assistance is needed in computation at (571) 272-3282.	oleting this form, (please contact Petitions	
The above-identified application became abandoned for failure taction by the United States Patent and Trademark Office. The date date of the period set for reply in the office notice or action plus an	e of abandonmer	nt is the day after the expira	
APPLICANT HEREBY PETITIONS FOR REVIV	'AL OF THIS API	PLICATION	
NOTE: A grantable petition requires the following item (1) Petition fee; (2) Reply and/or issue fee; (3) Terminal disclaimer with disclaimer fee - re filed before June 8, 1995; and for all design (4) Statement that the entire delay was uninter	quired for all utili applications; ar		
1.Petition fee Small entity-fee \$ (37 CFR 1.17(m)). Applicant class Other than small entity – fee \$ (37 CFR 1.17(m)).	74	status. See 37 CFR 1.27.	43087
Reply and/or fee A. The reply and/or fee to the above-noted Office action the form of AMENDMENT UNDER RULE 111	01 Fi in	C:1453 ify type of reply):	1500.00 0
has been filed previously on is enclosed herewith.	 ·		
B. The issue fee and publication fee (if applicable) of \$ has been paid previously on is enclosed herewith.			

[Page 1 of 2]

This collection of information is required by 37 CFR 1.137(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Petition, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/64 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Terminal disclaimer with disclaimer fee				
Since this utility/plant application was filed on or after June 8, 1995,	no terminal disclaimer is required.			
A terminal disclaimer (and disclaimer fee (37 CFR 1.20(d)) of \$				
for other than a small entity) disclaiming the required period of time is enclosed herewith (see PTO/SB/63).				
4. STATEMENT: The entire delay in filing the required reply from the due d				
filing of a grantable petition under 37 CFR 1.137(b) was unintentional. [NOTE: The United States Patent and				
Trademark Office may require additional information if there is a question as to whether either the				
abandonment or the delay in filing a petition under 37 CFR 1.137(b) was unintentional (MPEP 711.03(c), subsections (III)(C) and (D)).]				
WARNING:				
Petitioner/applicant is cautioned to avoid submitting personal information in docu contribute to identity theft. Personal information such as social security numb numbers (other than a check or credit card authorization form PTO-2038 submitted the USPTO to support a petition or an application. If this type of personal information USPTO, petitioners/applicants should consider redacting such personal information to the USPTO. Petitioners/applicant is advised that the record of a petert application	ers, bank account numbers, or credit card I for payment purposes) is never required by on is included in documents submitted to the I from the documents before submitting them			
to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance				
of a patent. Furthermore, the record from an abandoned application may also be	e available to the public if the application is			
referenced in a published application or an issued patent (see 37 CFR 1.14). Cher 2038 submitted for payment purposes are not retained in the application file and the				
2000 subtrimed for payment purposes are that retained in the application line and the	refore are not publicly available.			
Wertin f. W. Joell	MARCH 14, 2007			
Signature	Date			
WERTEN F.W. BELLAMY	27,029			
Typed or printed name	Registration Number, if applicable			
. % E - m - m - m - m - m - m - m - m - m -				
2635 FOX MILL ROAD	(703) 231-4216			
Address	Telephone Number			
RESTON, VIRGINIA 20191				
Address				
Enclosures: 🗸 Fee Payment				
✓ Reply				
Terminal Disclaimer Form				
Additional sheets containing statements establishing unintentional delay				
Other:				
Other				
CERTIFICATE OF MAILING OR TRANSMISSION	N [37 CFR 1.8(a)]			
I hereby certify that this correspondence is being:	•			
Deposited with the United States Postal Service on the date shown below with sufficient				
postage as first class mail in an envelope addressed to: Mail Stop Petition, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.				
Transmitted by facsimile on the date shown below to the United States Patent/and Trademark				
Office at (571) 273-8300.				
MARCH 14, 2007				
Date / Signature / WERTEN F.W. BELLAMY				
Typed or printed name of person signing certificate				
. year of printed har	1. p 0.00 0.g.m.g 00			

[Page 2 of 2]

Subj:

(no subject)

3/13/2007 11:13:12 () () Date:

From: To:

Wertenf Wertenf

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

MAR 1 6 2007

IN RE APPLICATION OF ROLF BUNGER, ET AL.

SERIAL NO.: 10/643,080

FILED: AUGUST 19, 2003

FOR: CELLULAR PHOSPHORYLATION POTENTIAL ENHANCING COMPOSISITIONS, PREPARATION AND

ท์ Daylight Time

USE THEREOF

APPLICATION FILED UNDER 37 CFR 111

MAIL STOP PATENT APPLICATION COMMISSIONER OF PATENTS AND TRADEMARKS P.O. BOX 1450 **ALEXANDRIA, VA 22313-1450**

SIR:

THIS IS IN RESPONSE TO THE OFFICE ACTION MAILES FROM THE U.S. PATENT AND TRADEMARK OFFICE ON SEPTEMBER 13, 2006.

APPLICANTS WOULD TO ACKNOWLEDGE WITH SINCERE APPRECIATION THE COURTESIES EXTENDED TO THEIR REPRESENTATIVE DURING THE TELEPHONE CONVERSATION ON MARCH 13, 2006. ADDITIONALLY, IT IS NOTED THAT ALL CLAIMS REMAINING IN THIS CASE ARE CLEAR OF PRIOR ART REJECTIONS, EXCEPT FOR THE 2 BUNGER PATENTS U.S. 5,536,751 AND U.S. 5,714,515. BOTH OF THESE REJECTIONS HAVE BEEN OBVIATED BY THE FILING OF TERMINAL DISCLAIMERS FOR EACH OF SAID BUNGER PATENTS. FURTHER, THE INSTANT APPLICATION IS CLAIMING THE BENEFIT OF THE EARLIEST FILING DATE OF THESES BUNGER CITED BY THE EXAMINER. THE EXAMINER IS REMINDED THAT CONTINUITY EXIST BETWEEN THIS JOINTLY FILED C-I-P AND BOTH BUNGER PATENTS AND THESES 2 PATENTS ALONG WITH ALL INTERVENING PATENT APPLICATIONS HAVE INCORPORATED BY REFERENCE INTO THE INSTANT CASE. (PLEASE SEE DEFINITION FOR C-I-P APPLICATIONS IN THE MPEP)

IN THE CLAIMS:

IN CLAIM 1, LINE 2, AFTER THE WORD "to", delete the words " prevent and/or";

PLEASE ADD NEW 20:

—CLAIM 20. A method on accordance with Claim 1, wherein the composition is a parenteral fluid.—

REMARKS

CLAIMS 1 TO 5 AND 7 TO 20 ARE IN THIS CASE. BASIS FOR CLAIM IS FOUND ON PAGE 32, LINE 12.

THE REJECTION OF CLAIMS 1 TO 19 UNDER 35 USC 112, FIRST PARAGRAPH FOR THE INCLUSION OF THE WORD "PREVENT" HAS BE OBVIATED BY AMENDING THE CLAIMS TO INCLUD ONLY TREATMENT OF CELLS AS SUGGESTED BY THE EXAMINER.

- THE REJECTION OF CLAIMS 1 TO 19BASED ON DOUBLE PATENTING HAS BEEN OBVIATED BY FILING 2 TERMINAL DISCLAIMERS IN THIS CASE.
- THE REJECTION OF CLAIMS 1 TO 5, 8, 10 AND UNDER 35USC102(E) HAVE BEEN OBVIATED BY CLAIMING THE BENEFIT OF THE FILING DATES OF THE PARENT CASES.

ACCORDINGLY, ALL CLAIMS SHOULD BE ALLOWED AND SUCH ACTION IS EARNESTLY SOLICITED.

RESPECTFULLY SUBMITTED.

WERTEN F.W. BELLAMY, REG. NO. 27,029

AOL now offers free email to everyone. Find out more about what's free from AOL at AOL.com.